- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Largest-Ever Precision Medicine Oncology Trial Ready for Launch
A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer type aims to simultaneously test the efficacy of more than 20 drugs.
A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer type aims to simultaneously test the efficacy of more than 20 drugs, in an ambitious National Cancer Institute (NCI) plan to further propel oncology drug discovery into the precision medicine era.
Starting in July, the NCI-MATCH trial will seek to recruit 1000 adults 18 years or older with progressive advanced solid tumors and lymphomas that are either refractory to standard therapy or for which there is no standard therapy. Participants will be assigned to small phase 2 trials based on molecular tumor profiling of specimens from biopsies conducted at the time of study entry.
The trial is “a critical and leading part” of the nation’s precision medicine initiative, Clifford A. Hudis, MD, FACP, said during a press briefing at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, where NCI-MATCH and other innovative research projects were detailed.
“In oncology, we’ve embraced this idea for years,” said Hudis, a past president of ASCO and a breast cancer specialist at Memorial Sloan Kettering Cancer Center. “The initiatives that we’re discussing today reflect not a new initiative, but an expansion of an ongoing dream that we have been pursuing.”
“This is the largest and most rigorous precision oncology trial that’s ever been attempted,” said James H. Doroshow, MD, the NCI’s deputy director.
Read more at OncLive.
Neonatology Pricing and Network Participation Under State Balance Billing Regulations
October 2nd 2025This national study of neonatology services found no clear evidence that state surprise billing regulations influenced prices or provider network participation for the commercially insured.
Read More
Managed Care Reflections: A Q&A With Ge Bai, PhD, CPA
October 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care, each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The October issue features a conversation with Ge Bai, PhD, CPA, professor of accounting at Johns Hopkins Carey Business School and professor of health policy and management at Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.
Read More
